Statistik Asas
| LEI | 549300IKDPIED8J8IG21 |
| CIK | 873303 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Sarepta Therapeutics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 29, 2025 |
EX-4.1 Exhibit 4.1 Execution Version SAREPTA THERAPEUTICS, INC., as Issuer AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of August 28, 2025 4.875% Convertible Senior Notes due 2030 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01. Definitions 1 Section 1.02. References to Interest 15 ARTICLE 2 ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF N |
|
| August 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2025 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2025 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 6, 2025 |
Calculation of Filing Fee Tables S-8 Sarepta Therapeutics, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan, as amended-Common Stock, par value $0.0001 per shar |
|
| August 6, 2025 |
As filed with the Securities and Exchange Commission on August 6, 2025 S-8 As filed with the Securities and Exchange Commission on August 6, 2025 Registration No. |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREPTA THE |
|
| July 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2025 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| July 16, 2025 |
Exhibit 99.1 Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label • After strategic review, Sarepta focuses pipeline on high-impact programs, prioritizing potentially best-in-class siRNA platform assets • Strategic restructuring includes reduced operating expenses, delivering approxim |
|
| July 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2025 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 6, 2025 |
Amendment No. 4 to the Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan Exhibit 10.1 AMENDMENT NO. 4 TO THE SAREPTA THERAPEUTICS, INC. 2018 EQUITY INCENTIVE Plan WHEREAS, Sarepta Therapeutics, Inc. (the “Company”) previously adopted and approved the 2018 Equity Incentive Plan (the “Plan”); WHEREAS, the Plan was previously amended by that certain Amendment No. 1, approved by the Board of Directors of the Company (the “Board”) on April 3, 2020 and the Company’s stockhol |
|
| June 6, 2025 |
Exhibit 10.2 AMENDMENT NO. 3 TO THE SAREPTA THERAPEUTICS, INC. AMENDED AND RESTATED 2013 EMPLOYEE STOCK PURCHASE PLAN (AS AMENDED AND RESTATED ON JUNE 27, 2016) WHEREAS, Sarepta Therapeutics, Inc. (the “Company”) previously adopted and approved the Amended and Restated 2013 Employee Stock Purchase Plan (as Amended and Restated as of June 27, 2016) (the “Plan”); WHEREAS, the Plan was amended by tha |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 05, 2025 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREPTA TH |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 3, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Sarepta Therapeutics, Inc. |
|
| March 3, 2025 |
As filed with the Securities and Exchange Commission on March 3, 2025 Table of Contents As filed with the Securities and Exchange Commission on March 3, 2025 Registration No. |
|
| February 28, 2025 |
Subsidiaries of the Registrant. EXHIBIT 21.1 Sarepta Therapeutics, Inc. Subsidiaries of the Registrant Name Jurisdiction of Incorporation Sarepta Securities Corp. Massachusetts, USA ST International Holdings, Inc. Delaware, USA ST International Holdings Two, Inc. Delaware, USA Sarepta Therapeutics Two, LLC Delaware, USA Sarepta Therapeutics Three, LLC Delaware, USA Sarepta Therapeutics Ireland LLP Ireland Sarepta Therapeutics Ir |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number : 001-14895 Sarepta Thera |
|
| February 28, 2025 |
Sarepta Therapeutics, Inc. Insider Trading Policy Exhibit 19.1 SAREPTA THERAPEUTICS, INC. INSIDER TRADING POLICY 1. Purpose. This Insider Trading Policy (this “Policy”) provides guidelines with respect to transactions in the securities of Sarepta Therapeutics, Inc. (the “Company”) and the handling of confidential information about the Company and the companies with which the Company does business. The Company’s Board of Directors (the “Board”) ha |
|
| February 28, 2025 |
Exhibit 10.67 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Exclusive License and Collaboration Agreement By and Between Arrowhead Pharmaceuticals, Inc. and Sarepta Therapeutics, Inc. November 25, 2024 -1- [***] = CERTAIN CONFIDENTIA |
|
| February 26, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 26, 2025 |
For the Three Months Ended December 31, Exhibit 99.1 Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate Developments – Net product revenues for the fourth quarter 2024 totaled $638.2 million, a 75% increase over the same quarter of the prior year – ELEVIDYS net product revenue for the quarter totaled $384.2 million; Royalty revenue from the sales of ELEVIDYS by Roche for the quarter t |
|
| February 14, 2025 |
EX-99.4 4 ck0001669811-ex994.htm EX-99.4 INvestor RIGHTS AGREEMENT This Investor Rights Agreement (this “Agreement”) is made and entered into as of February 7, 2025, by and between Arrowhead Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Sarepta Therapeutics Investments, Inc., a Delaware corporation (the “Purchaser”). NOW, THEREFORE, IN CONSIDERATION of the mutual covenants con |
|
| February 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2025 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 14, 2025 |
Schedule A Executive Officers and Directors of Sarepta Therapeutics, Inc. EX-99.A 5 ck0001669811-ex99a.htm EX-99.A Schedule A Executive Officers and Directors of Sarepta Therapeutics, Inc. Name Citizenship Position / Principal Occupation Principal Business Address Douglas S. Ingram United States President and Chief Executive Officer c/o Sarepta Therapeutics, Inc., 215 First Street, Suite 415, Cambridge, MA 02142 Ian M. Estepan United States Executive Vice President, Chi |
|
| February 14, 2025 |
Exhibit 10.1 CREDIT AGREEMENT dated as of February 13, 2025 among SAREPTA THERAPEUTICS, INC., as Borrower The Lenders Party Hereto JPMORGAN CHASE BANK, N.A. as Administrative Agent, JPMORGAN CHASE BANK, N.A., BARCLAYS BANK PLC, CITIZENS BANK, N.A., GOLDMAN SACHS BANK USA, MORGAN STANLEY SENIOR FUNDING, INC., AND ROYAL BANK OF CANADA as Joint Lead Arrangers and Joint Bookrunners, BARCLAYS BANK PLC, |
|
| February 14, 2025 |
EX-99.3 3 ck0001669811-ex993.htm EX-99.3 Execution Version STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (this “Agreement”) is entered into as of November 25, 2024, by and among Arrowhead Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Sarepta Therapeutics Investments, Inc., a Delaware corporation (“Purchaser” and, together with the Company, the “Parties”). RECITALS WHE |
|
| February 14, 2025 |
EX-99.1 2 ck0001669811-ex991.htm EX-99.1 Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13D referred to below) on behalf of each of them of a statement on Schedule 13D (including amendments thereto exe |
|
| January 13, 2025 |
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue EX-99.1 Exhibit 99.1 Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue • Preliminary total net product revenue of $638.2 million for the fourth quarter and $1.79 billion for full-year 2024, exceeding full-year guidance by over $100 million • Preliminary ELEVIDYS net product revenue totaled $384.2 million for the fourth quarter, exceeding guidance by ov |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 24, 2024 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Sarepta Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 803607100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| November 6, 2024 |
Exhibit 10.2 SAREPTA THERAPEUTICS, INC. BY EMAIL September 16, 2024 JPMorgan Chase Bank, National Association London Branch 25 Bank Street Canary Wharf London E14 5JP England Re: Supplement to Base Capped Call Option Transaction Confirmation and Additional Capped Call Option Transaction Confirmation To Whom It May Concern: Reference is made to (i) that certain base call option transaction confirma |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREPT |
|
| November 6, 2024 |
Exhibit 10.1 SAREPTA THERAPEUTICS, INC. BY EMAIL September 16, 2024 Goldman Sachs & Co. LLC 200 West Street New York, NY 10282-2198 Attention: Josh Murray, Equity Capital Markets Telephone No.: [**] Re: Supplement to Base Capped Call Option Transaction Confirmation and Additional Capped Call Option Transaction Confirmation To Whom It May Concern: Reference is made to (i) that certain base call opt |
|
| September 16, 2024 |
Amendment No. 1 to the Second Amended and Restated Bylaws Exhibit 3.1 AMENDMENT NO. 1 TO SECOND AMENDED AND RESTATED BYLAWS OF SAREPTA THERAPEUTICS, INC. (a Delaware corporation) Effective as of September 12, 2024, the Second Amended and Restated Bylaws (the “Bylaws”) of Sarepta Therapeutics, Inc., a Delaware corporation, are hereby amended by replacing the text of Article III, Section 3.02 with the following: “The authorized number of directors shall be |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2024 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Comm |
|
| August 7, 2024 |
Exhibit 107 Calculation of filing Fee Tables Form S-8 (Form Type) Sarepta Therapeutics, Inc. |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREPTA THE |
|
| August 7, 2024 |
As filed with the Securities and Exchange Commission on August 7, 2024 As filed with the Securities and Exchange Commission on August 7, 2024 Registration No. |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 7, 2024 |
Amendment No. 1 to the Sarepta Therapeutics, Inc. 2024 Employment Commencement Incentive Plan Exhibit 10.1 AMENDMENT NO. 1 TO THE SAREPTA THERAPEUTICS, INC. 2024 EMPLOYMENT COMMENCEMENT INCENTIVE PLAN WHEREAS, Sarepta Therapeutics, Inc. (the “Company”) previously adopted and approved the 2024 Employment Commencement Incentive Plan (the “Plan”) as an inducement stock plan under Nasdaq Stock Market Rule 5635(c)(4) to, among other things, attract and retain the best candidates for positions o |
|
| May 1, 2024 |
Exhibit 10.2 SAREPTA THERAPEUTICS, INC. 2024 EMPLOYMENT COMMENCEMENT INCENTIVE PLAN STOCK OPTION AWARD AGREEMENT Unless otherwise defined herein, the terms defined in the 2024 Employment Commencement Incentive Plan (the “Plan”) will have the same defined meanings in this Stock Option Award Agreement (the “Award Agreement”). NOTICE OF STOCK OPTION GRANT Participant Name: [●] Address: [●] You have b |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREPTA TH |
|
| May 1, 2024 |
Exhibit 10.3 SAREPTA THERAPEUTICS, INC. 2024 EMPLOYMENT COMMENCEMENT INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT Unless otherwise defined herein, the terms defined in the 2024 Employment Commencement Incentive Plan (the “Plan”) will have the same defined meanings in this Restricted Stock Unit Award Agreement (the “Award Agreement”). NOTICE OF RESTRICTED STOCK UNIT GRANT Participant: [Name |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 28, 2024 |
As filed with the Securities and Exchange Commission on March 28, 2024 As filed with the Securities and Exchange Commission on March 28, 2024 Registration No. |
|
| March 28, 2024 |
Sarepta Therapeutics, Inc. 2024 Employment Commencement Incentive Plan Exhibit 4.5 SAREPTA THERAPEUTICS, INC. 2024 EMPLOYMENT COMMENCEMENT INCENTIVE PLAN 1. Purposes of the Plan. (a) Eligible Award Recipients. Only Eligible Participants may receive awards under the Plan. (b) The purposes of this Plan are: (i) to attract and retain the best available Eligible Participants for positions of substantial responsibility upon whose judgment, interest, and special effort the |
|
| March 28, 2024 |
Consent of Ropes & Gray LLP (included in Exhibit 5.5) EX-5.5 Exhibit 5.5 ROPES & GRAY LLP PRUDENTIAL TOWER 800 BOYLSTON STREET BOSTON, MA 02199-3600 WWW.ROPESGRAY.COM March 28, 2024 Sarepta Therapeutics, Inc. 215 First Street, Suite 415 Cambridge, Massachusetts 02142 Ladies and Gentlemen: This opinion letter is furnished to you in connection with the Post-Effective Amendment No. 1 to the Registration Statements on Form S-8, Reg. Nos. 333-240996, 333- |
|
| March 28, 2024 |
Consent of Ropes & Gray LLP (included in Exhibit 5.5) EX-5.5 Exhibit 5.5 ROPES & GRAY LLP PRUDENTIAL TOWER 800 BOYLSTON STREET BOSTON, MA 02199-3600 WWW.ROPESGRAY.COM March 28, 2024 Sarepta Therapeutics, Inc. 215 First Street, Suite 415 Cambridge, Massachusetts 02142 Ladies and Gentlemen: This opinion letter is furnished to you in connection with the Post-Effective Amendment No. 1 to the Registration Statements on Form S-8, Reg. Nos. 333-240996, 333- |
|
| March 28, 2024 |
As filed with the Securities and Exchange Commission on March 28, 2024 As filed with the Securities and Exchange Commission on March 28, 2024 Registration No. |
|
| March 28, 2024 |
As filed with the Securities and Exchange Commission on March 28, 2024 As filed with the Securities and Exchange Commission on March 28, 2024 Registration No. |
|
| March 28, 2024 |
Consent of Ropes & Gray LLP (included in Exhibit 5.5) EX-5.5 Exhibit 5.5 ROPES & GRAY LLP PRUDENTIAL TOWER 800 BOYLSTON STREET BOSTON, MA 02199-3600 WWW.ROPESGRAY.COM March 28, 2024 Sarepta Therapeutics, Inc. 215 First Street, Suite 415 Cambridge, Massachusetts 02142 Ladies and Gentlemen: This opinion letter is furnished to you in connection with the Post-Effective Amendment No. 1 to the Registration Statements on Form S-8, Reg. Nos. 333-240996, 333- |
|
| March 28, 2024 |
Sarepta Therapeutics, Inc. 2024 Employment Commencement Incentive Plan Exhibit 4.5 SAREPTA THERAPEUTICS, INC. 2024 EMPLOYMENT COMMENCEMENT INCENTIVE PLAN 1. Purposes of the Plan. (a) Eligible Award Recipients. Only Eligible Participants may receive awards under the Plan. (b) The purposes of this Plan are: (i) to attract and retain the best available Eligible Participants for positions of substantial responsibility upon whose judgment, interest, and special effort the |
|
| March 28, 2024 |
Sarepta Therapeutics, Inc. 2024 Employment Commencement Incentive Plan Exhibit 4.5 SAREPTA THERAPEUTICS, INC. 2024 EMPLOYMENT COMMENCEMENT INCENTIVE PLAN 1. Purposes of the Plan. (a) Eligible Award Recipients. Only Eligible Participants may receive awards under the Plan. (b) The purposes of this Plan are: (i) to attract and retain the best available Eligible Participants for positions of substantial responsibility upon whose judgment, interest, and special effort the |
|
| March 28, 2024 |
Consent of Ropes & Gray LLP (included in Exhibit 5.5) EX-5.5 Exhibit 5.5 ROPES & GRAY LLP PRUDENTIAL TOWER 800 BOYLSTON STREET BOSTON, MA 02199-3600 WWW.ROPESGRAY.COM March 28, 2024 Sarepta Therapeutics, Inc. 215 First Street, Suite 415 Cambridge, Massachusetts 02142 Ladies and Gentlemen: This opinion letter is furnished to you in connection with the Post-Effective Amendment No. 1 to the Registration Statements on Form S-8, Reg. Nos. 333-240996, 333- |
|
| March 28, 2024 |
Sarepta Therapeutics, Inc. 2024 Employment Commencement Incentive Plan Exhibit 4.5 SAREPTA THERAPEUTICS, INC. 2024 EMPLOYMENT COMMENCEMENT INCENTIVE PLAN 1. Purposes of the Plan. (a) Eligible Award Recipients. Only Eligible Participants may receive awards under the Plan. (b) The purposes of this Plan are: (i) to attract and retain the best available Eligible Participants for positions of substantial responsibility upon whose judgment, interest, and special effort the |
|
| March 28, 2024 |
As filed with the Securities and Exchange Commission on March 28, 2024 As filed with the Securities and Exchange Commission on March 28, 2024 Registration No. |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number : 001-14895 Sarepta Thera |
|
| February 28, 2024 |
Exhibit 10.72 TWELFTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT This TWELFTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT (this “Twelfth Amendment”) is made and entered into as of July 28, 2022 (the “Twelfth Amendment Effective Date”) between Sarepta Therapeutics Three LLC, a limited liability company organized and existing under the laws of the State of Delaware, Unit |
|
| February 28, 2024 |
Exhibit 10.74 FOURTEENTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT This FOURTEENTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT (this “Fourteenth Amendment”) is made and entered into as of October 31, 2022 (the “Fourteenth Amendment Effective Date”) between Sarepta Therapeutics Three LLC, a limited liability company organized and existing under the laws of the State of |
|
| February 28, 2024 |
Sarepta Therapeutics Inc.'s Policy for Recoupment of Incentive Compensation Exhibit 10.77 SAREPTA THERAPEUTICS, INC. Policy for Recoupment of Incentive Compensation 1. Introduction In accordance with Section 10D of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the regulations thereunder, the Board of Directors (the “Board”) of Sarepta Therapeutics, Inc. (the “Company”) has adopted this policy (the “Policy”) providing for the Company’s recoupmen |
|
| February 28, 2024 |
Subsidiaries of the Registrant. EXHIBIT 21.1 Sarepta Therapeutics, Inc. Subsidiaries of the Registrant Name Jurisdiction of Incorporation Sarepta Securities Corp. Massachusetts, USA ST International Holdings Two, Inc. Delaware, USA Sarepta Therapeutics Three, LLC Delaware, USA |
|
| February 28, 2024 |
Exhibit 10.73 THIRTEENTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT This THIRTEENTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT (this “Thirteenth Amendment”) is made and entered into as of August 31, 2022 (the “Thirteenth Amendment Effective Date”) between Sarepta Therapeutics Three LLC, a limited liability company organized and existing under the laws of the State of |
|
| February 28, 2024 |
Exhibit 10.71 ELEVENTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT This ELEVENTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT (this “Eleventh Amendment”) is made and entered into as of June 23, 2022 (the “Eleventh Amendment Effective Date”) between Sarepta Therapeutics Three LLC, a limited liability company organized and existing under the laws of the State of Delaware, |
|
| February 13, 2024 |
SRPT / Sarepta Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01876-sareptatherapeuticsi.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Sarepta Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 803607100 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box |
|
| February 9, 2024 |
SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Sarepta Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 803607100 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| January 8, 2024 |
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue Exhibit 99.1 Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue – Preliminary total net product revenue is expected to total $1.145 billion for full-year 2023 – Preliminary ELEVIDYS net product revenue is expected to be $131.3 million for the fourth quarter and $200.4 million for full-year 2023, significantly exceeding consensus – Preliminary RNA-based |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 08, 2024 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREPT |
|
| August 2, 2023 |
Agreement between the Research Institute at Execution Version [**] = Identified information has been excluded from this exhibit because it is both (i) information that the Company customarily and actually treats as private or confidential and (ii) is not material. |
|
| August 2, 2023 |
As filed with the Securities and Exchange Commission on August 2, 2023 S-8 As filed with the Securities and Exchange Commission on August 2, 2023 Registration No. |
|
| August 2, 2023 |
Research Institute at Nationwide Children's Hospital [**] = Identified information has been excluded from this exhibit because it is both (i) information that the Company customarily and actually treats as private or confidential and (ii) is not material. |
|
| August 2, 2023 |
Exhibit 107 Calculation of filing Fee Tables Form S-8 (Form Type) Sarepta Therapeutics, Inc. |
|
| August 2, 2023 |
Research Institute at Nationwide Children's Hospital [**] = Identified information has been excluded from this exhibit because it is both (i) information that the Company customarily and actually treats as private or confidential and (ii) is not material. |
|
| August 2, 2023 |
Exhibit 10.5 FIRST AMENDMENT TO THE AMENDED AND RESTATED LEAD DMD PRODUCT MANUFACTURING & SUPPLY AGREEMENT This first amendment to the Amended and Restated Lead DMD Product Manufacturing & Supply Agreement (“First Amendment”) by and between Sarepta Therapeutics Three, LLC (“Sarepta”), and Catalent Maryland, Inc. (“Catalent”). WHEREAS, Sarepta and Catalent entered into that certain Amended and Rest |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREPTA THE |
|
| August 2, 2023 |
Catalent Maryland, Inc. and Sarepta Therapeutics Three, LLC EXECUTION COPY [**] = Identified information has been excluded from this exhibit because it is both (i) information that the Company customarily and actually treats as private or confidential and (ii) is not material. |
|
| June 22, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 22, 2023 |
Doug Ingram President and CEO Sarepta Therapeutics, Inc. (NASDAQ: SRPT) June 22, 2023 Exhibit 99.1 This presentation contains “forward-looking statements.” Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believe,” “anticipate,” “plan,” “expect,” “will,” “may,” “intend,” “prepare,” “look,” “potential,” “possible” and similar e |
|
| June 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 22, 2023 |
Exhibit 99.1 Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy ELEVIDYS (delandistrogene moxeparvovec-rokl) is approved for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne based on expression of ELEVIDYS micro-dystrophin observed in patients treated with ELEVIDYS ELEVIDYS is a one-time treatment |
|
| June 9, 2023 |
Therapeutics, Inc. Amended and Restated 2013 Exhibit 10.2 AMENDMENT NO. 2 TO THE SAREPTA THERAPEUTICS, INC. AMENDED AND RESTATED 2013 EMPLOYEE STOCK PURCHASE PLAN (AS AMENDED AND RESTATED ON JUNE 27, 2016) WHEREAS, Sarepta Therapeutics, Inc. (the “Company”) previously adopted and approved the Amended and Restated 2013 Employee Stock Purchase Plan (as Amended and Restated as of June 27, 2016) (the “Plan”); WHEREAS, the Plan was amended by tha |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 08, 2023 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 9, 2023 |
Amendment No.3 to the Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan Exhibit 10.1 AMENDMENT NO. 3 TO THE SAREPTA THERAPEUTICS, INC. 2018 EQUITY INCENTIVE Plan WHEREAS, Sarepta Therapeutics, Inc. (the “Company”) previously adopted and approved the 2018 Equity Incentive Plan (the “Plan”); WHEREAS, the Plan was previously amended by that certain Amendment No. 1, approved by the Board of Directors of the Company (the “Board”) on April 3, 2020 and the Company’s stockhol |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREPTA TH |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 24, 2023 |
DEFA14A 1 srptdefa14anotice.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a |
|
| March 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 3, 2023 |
EX-10.1 Exhibit 10.1 Exchange Agreement March 2, 2023 Sarepta Therapeutics, Inc. 1.50% Convertible Senior Notes due 2024 The undersigned investor (the “Investor”), for itself and, if applicable, on behalf of the beneficial owners listed on Exhibit A hereto (“Accounts”) for whom the Investor holds contractual and investment authority (each, including the Investor if it is a party exchanging Notes ( |
|
| February 28, 2023 |
Exhibit 10.73 SEPARATION AND CONSULTING AGREEMENT AND GENERAL RELEASE This Separation and Consulting Agreement and General Release (the “Agreement”) by and between Bill Ciambrone (“Employee”) and Sarepta Therapeutics, Inc. (the “Company”), is made effective as of the date following Employee’s signature and the expiration of the seven (7) day revocation period without revocation (the “Effective Dat |
|
| February 28, 2023 |
Exhibit 10.70 TENTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT This TENTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT (this “Tenth Amendment”) is made and entered into as of May 31, 2022 (the “Tenth Amendment Effective Date”) between Sarepta Therapeutics Three LLC, a limited liability company organized and existing under the laws of the State of Delaware, United States |
|
| February 28, 2023 |
Subsidiaries of the Registrant. EXHIBIT 21.1 Sarepta Therapeutics, Inc. Subsidiaries of the Registrant Name Jurisdiction of Incorporation Sarepta Securities Corp. Massachusetts, USA ST International Holdings Two, Inc. Delaware, USA Sarepta Therapeutics Three, LLC Delaware, USA |
|
| February 28, 2023 |
Letter Agreement, dated November 18, 2022, between Sarepta Therapeutics, Inc. and Douglas S. Ingram Exhibit 10.72 November 18, 2022 Mr. Douglas S. Ingram Re: Amendments to Employment Agreement Dear Doug: This letter agreement (“Letter Agreement”) amends, effective on the date above, certain terms of the Employment Agreement (the “Employment Agreement”) dated June 26, 2017 between you and Sarepta Therapeutics, Inc. (the “Company”). This Letter Agreement is intended to relate to the Letter Agreeme |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number : 001-14895 Sarepta Thera |
|
| February 14, 2023 |
SRPT / Sarepta Therapeutics Inc / SANDS CAPITAL MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO Section 240. |
|
| February 9, 2023 |
SRPT / Sarepta Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01845-sareptatherapeuticsi.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Sarepta Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 803607100 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box |
|
| January 9, 2023 |
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues EX-99.1 2 srpt-ex991.htm EX-99.1 Exhibit 99.1 Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues – The Company expects to exceed 2022 full-year guidance for net product revenues – Preliminary net product revenues for the fourth quarter and full-year 2022 are expected to total $235.5 million and $843.3 million, respectively – Preliminary year-end 2022 c |
|
| January 9, 2023 |
EX-99.2 3 srpt-ex992.htm EX-99.2 Sarepta Therapeutics, Inc. (NASDAQ:SRPT) JPMorgan Healthcare Conference San Francisco, California January 9, 2023 Doug Ingram President and CEO Exhibit 99.2 Forward-looking statements This presentation contains "forward-looking statements." Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “belie |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 09, 2023 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 13, 2022 |
Second Amended and Restated Bylaws Exhibit 3.1 SECOND AMENDED AND RESTATED BYLAWS OF SAREPTA THERAPEUTICS, INC. (a Delaware corporation) Effective December 9, 2022 TABLE OF CONTENTS CONTENTS Article I. CORPORATE OFFICES Section 1.01 REGISTERED OFFICE. Section 1.02 OTHER OFFICES. Article II. MEETINGS OF STOCKHOLDERS Section 2.01 PLACE OF MEETINGS. Section 2.02 ANNUAL MEETING. Section 2.03 SPECIAL MEETING. Section 2.04 ADVANCE NOTICE |
|
| December 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2022 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREPT |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2022 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commis |
|
| September 19, 2022 |
Exhibit 10.9 Execution Version GOLDMAN SACHS & CO. LLC | 200 WEST STREET | NEW YORK, NEW YORK 10282-2198 | TEL: 212-902-1000 To: Sarepta Therapeutics, Inc. 215 First Street, Suite 415 Cambridge, MA 02142 Attention: General Counsel Telephone No.: (617) 274-4000 From: Goldman Sachs & Co. LLC Re: Additional Call Option Transaction Date: September 14, 2022 The purpose of this letter agreement (this ?C |
|
| September 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2022 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Comm |
|
| September 19, 2022 |
Exhibit 10.5 Execution Version Mizuho Markets Americas LLC c/o Mizuho Securities USA LLC, as agent 1271 Avenue of the Americas New York, NY 10020 To: Sarepta Therapeutics, Inc. 215 First Street, Suite 415 Cambridge, MA 02142 Attention: General Counsel Telephone No.: (617) 274-4000 From: Mizuho Markets Americas LLC Re: Base Call Option Transaction Date: September 13, 2022 The purpose of this letter |
|
| September 19, 2022 |
Exhibit 10.2 PURCHASE AGREEMENT Michael A. Chamber Living Trust (the ?Purchaser?), is entering into this Purchase Agreement (the ?Agreement?) with Sarepta Therapeutics, Inc. (the ?Company?) on September 13, 2022, whereby the Purchaser will purchase (the ?Purchase?) the Company?s 1.25% Convertible Senior Notes due 2027 (the ?Notes?) having the terms set forth in the Notes that will be issued pursua |
|
| September 19, 2022 |
Exhibit 10.10 Execution Version Mizuho Markets Americas LLC c/o Mizuho Securities USA LLC, as agent 1271 Avenue of the Americas New York, NY 10020 To: Sarepta Therapeutics, Inc. 215 First Street, Suite 415 Cambridge, MA 02142 Attention: General Counsel Telephone No.: (617) 274-4000 From: Mizuho Markets Americas LLC Re: Additional Call Option Transaction Date: September 14, 2022 The purpose of this |
|
| September 19, 2022 |
Exhibit 10.8 Execution Version Barclays Bank PLC 5 The North Colonnade Canary Wharf, London E14 4BB Facsimile: +44(20)77736461 Telephone: +44 (20) 777 36810 c/o Barclays Capital Inc. as Agent for Barclays Bank PLC 745 Seventh Avenue New York, NY 10019 Telephone: +1 212 526 7000 To: Sarepta Therapeutics, Inc. 215 First Street, Suite 415 Cambridge, MA 02142 Attention: General Counsel Telephone No.: |
|
| September 19, 2022 |
Exhibit 10.11 Execution Version Morgan Stanley & Co. LLC 1585 Broadway, 4th Floor New York, NY 10036 To: Sarepta Therapeutics, Inc. 215 First Street, Suite 415 Cambridge, MA 02142 Attention: General Counsel Telephone No.: (617) 274-4000 From: Morgan Stanley & Co. LLC Re: Additional Call Option Transaction Date: September 14, 2022 The purpose of this letter agreement (this ?Confirmation?) is to con |
|
| September 19, 2022 |
Exhibit 10.4 Execution Version GOLDMAN SACHS & CO. LLC | 200 WEST STREET | NEW YORK, NEW YORK 10282-2198 | TEL: 212-902-1000 To: Sarepta Therapeutics, Inc. 215 First Street, Suite 415 Cambridge, MA 02142 Attention: General Counsel Telephone No.: (617) 274-4000 From: Goldman Sachs & Co. LLC Re: Base Call Option Transaction Date: September 13, 2022 The purpose of this letter agreement (this ?Confirm |
|
| September 19, 2022 |
Exhibit 4.1 Execution Version SAREPTA THERAPEUTICS, INC., as Issuer AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of September 16, 2022 1.250% Convertible Senior Notes due 2027 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01. Definitions 1 Section 1.02. References to Interest 14 ARTICLE 2 ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES |
|
| September 19, 2022 |
Exhibit 10.1 SAREPTA THERAPEUTICS, INC. 1.25% Convertible Senior Notes due 2027 Purchase Agreement September 13, 2022 Goldman Sachs & Co. LLC J.P. Morgan Securities LLC As Representatives of the several Initial Purchasers listed in Schedule 1 hereto c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Ladies |
|
| September 19, 2022 |
Exhibit 10.6 Execution Version Morgan Stanley & Co. LLC 1585 Broadway, 4th Floor New York, NY 10036 To: Sarepta Therapeutics, Inc. 215 First Street, Suite 415 Cambridge, MA 02142 Attention: General Counsel Telephone No.: (617) 274-4000 From: Morgan Stanley & Co. LLC Re: Base Call Option Transaction Date: September 13, 2022 The purpose of this letter agreement (this ?Confirmation?) is to confirm th |
|
| September 19, 2022 |
Exhibit 10.7 Execution Version RBC Capital Markets, LLC as Agent for Royal Bank of Canada Brookfield Place 200 Vesey Street New York, NY 10281-1021 Telephone: (212) 858-7000 To: Sarepta Therapeutics, Inc. 215 First Street, Suite 415 Cambridge, MA 02142 Attention: General Counsel Telephone No.: (617) 274-4000 From: RBC Capital Markets, LLC, as Agent for Royal Bank of Canada Re: Base Call Option Tra |
|
| September 19, 2022 |
Exhibit 10.3 Execution Version Barclays Bank PLC 5 The North Colonnade Canary Wharf, London E14 4BB Facsimile: +44(20)77736461 Telephone: +44 (20) 777 36810 c/o Barclays Capital Inc. as Agent for Barclays Bank PLC 745 Seventh Avenue New York, NY 10019 Telephone: +1 212 526 7000 To: Sarepta Therapeutics, Inc. 215 First Street, Suite 415 Cambridge, MA 02142 Attention: General Counsel Telephone No.: |
|
| September 19, 2022 |
Exhibit 10.12 Execution Version RBC Capital Markets, LLC as Agent for Royal Bank of Canada Brookfield Place 200 Vesey Street New York, NY 10281-1021 Telephone: (212) 858-7000 To: Sarepta Therapeutics, Inc. 215 First Street, Suite 415 Cambridge, MA 02142 Attention: General Counsel Telephone No.: (617) 274-4000 From: RBC Capital Markets, LLC, as Agent for Royal Bank of Canada Re: Additional Call Opt |
|
| August 2, 2022 |
Exhibit 107 Calculation of filing Fee Tables Form S-8 (Form Type) Sarepta Therapeutics, Inc. |
|
| August 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREPTA THE |
|
| August 2, 2022 |
EXHIBIT 10.2 NINTH Amendment to License, Collaboration, and Option Agreement This NINTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT (this “Ninth Amendment”) is made and entered into as of March 23, 2022 (the “Ninth Amendment Effective Date”) between Sarepta Therapeutics Three LLC, a limited liability company organized and existing under the laws of the State of Delaware, United State |
|
| August 2, 2022 |
As filed with the Securities and Exchange Commission on August 2, 2022 As filed with the Securities and Exchange Commission on August 2, 2022 Registration No. |
|
| June 3, 2022 |
Amendment No. 2 to the Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan Exhibit 10.1 AMENDMENT NO. 2 TO THE SAREPTA THERAPEUTICS, INC. 2018 EQUITY INCENTIVE Plan WHEREAS, Sarepta Therapeutics, Inc. (the ?Company?) previously adopted and approved the 2018 Equity Incentive Plan (the ?Plan?); WHEREAS, the Plan was previously amended by that certain Amendment No. 1, approved by the Board of Directors of the Company (the ?Board?) on April 3, 2020 and the Company?s stockhol |
|
| June 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 02, 2022 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREPTA TH |
|
| May 4, 2022 |
Exhibit 10.1 SAREPTA THERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT NOTICE OF PERFORMANCE-BASED RESTRICTED STOCK UNIT GRANT Participant: [Name of Participant] Address: The above-named Participant (the ?Participant?) has been granted the number of performance-based restricted stock units (the ?PSUs?) set forth below giving the Participant the c |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 21, 2022 |
Letter Agreement, dated April 19, 2022, between Sarepta Therapeutics, Inc. and Douglas S. Ingram Exhibit 10.1 EXECUTION VERSION April 19, 2022 Mr. Douglas S. Ingram c/o Sarepta Therapeutics, Inc. 215 First Street Cambridge, MA 02142 Re: Amendments to Performance Stock Option Award Agreement, Change in Control and Severance Agreement and Employment Agreement relating to Performance Stock Option Dear Doug: This letter agreement (?Letter Agreement?) amends, effective on the date above, certain t |
|
| April 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2022 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| April 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 2, 2022 |
As filed with the Securities and Exchange Commission on March 2, 2022 Table of Contents As filed with the Securities and Exchange Commission on March 2, 2022 Registration No. |
|
| March 2, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Sarepta Therapeutics, Inc. |
|
| March 1, 2022 |
DocuSign Envelope ID: 09DF38C8-DF3F-4CFE-A990-D755920F43B3 Exhibit 10.65 SEPARATION AGREEMENT AND GENERAL RELEASE This Separation Agreement and General Release (the ?Agreement?) by and between Gilmore O?Neill (?Employee?) and Sarepta Therapeutics, Inc. (the ?Company?), is made effective as of the date following Employee?s signature and the expiration of the seven (7) day revocation period without |
|
| March 1, 2022 |
between Sarepta Therapeutics Three, LLC and F. Hoffman-La Roche Ltd, dated December 21, 2019 DocuSign Envelope ID: D9277ED3-955A-426C-B021-BDA2E6B1CB05 Exhibit 10.62 SIXTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT This SIXTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT (this ?Sixth Amendment?) is made and entered into as of November 30, 2021 (the ?Sixth Amendment Effective Date?) between Sarepta Therapeutics Three LLC, a limited liability company organized and |
|
| March 1, 2022 |
DocuSign Envelope ID: 118F1C3C-AB1A-4635-B0F9-E8EBF3E1D40D Exhibit 10.64 EIGHTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT This EIGHTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT (this ?Eighth Amendment?) is made and entered into as of January 28, 2022 (the ?Eighth Amendment Effective Date?) between Sarepta Therapeutics Three LLC, a limited liability company organized |
|
| March 1, 2022 |
Subsidiaries of the Registrant. EXHIBIT 21.1 Sarepta Therapeutics, Inc. Subsidiaries of the Registrant Name Jurisdiction of Incorporation Sarepta Securities Corp. Massachusetts, USA ST International Holdings Two, Inc. Delaware, USA Sarepta Therapeutics Three, LLC Delaware, USA |
|
| March 1, 2022 |
DocuSign Envelope ID: EA350C36-E900-4606-87D9-B0A4B2C2E752 Roche Draft 1/6/2021 Exhibit 10. |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number : 001-14895 Sarepta Thera |
|
| March 1, 2022 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO SAREPTA THERAPEUTICS, INC. |
|
| February 10, 2022 |
SRPT / Sarepta Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Sarepta Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 803607100 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| January 10, 2022 |
Exhibit 99.1 Sarepta Therapeutics? Gene Therapy SRP-9001 Shows Statistically Significant Functional Improvements Compared to Pre-specified Matched External Control in Part 2 of Study SRP-9001-102 for the Treatment of Duchenne Muscular Dystrophy ? Participants from the placebo crossover group in Part 2 of Study SRP-9001-102, scored 2.0 points higher on the mean North Star Ambulatory Assessment (NSA |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 10, 2022 |
DOUG INGRAM President and CEO J.P. Morgan 40th Annual Healthcare Conference January 10, 2022 Exhibit 99.2 Forward-looking Statements This presentation contains "forward-looking statements." Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as ?believe,? ?anticipate,? ?plan,? ?expect,? ?will,? ?may,? ?intend,? ?prepare,? ?look,? ?po |
|
| November 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREPT |
|
| November 3, 2021 |
EX-10.1 2 srpt-ex101.htm EX-10.1 EXHIBIT 10.1 FIFTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT This FIFTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT (this “Fifth Amendment”) is made and entered into as of August 31, 2021 (the “Fifth Amendment Effective Date”) between Sarepta Therapeutics Three LLC, a limited liability company organized and existing under the laws of t |
|
| October 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2021 Sarepta Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-14895 93-0797222 (State or other Jurisdiction of Incorporation) (Commis |
|
| October 15, 2021 |
Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock EX-99.2 5 d228298dex992.htm EX-99.2 Exhibit 99.2 Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (Nasdaq:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it is offering to sell, subject to market and other conditions, $500,000,000 in shares of it |
|
| October 15, 2021 |
Exhibit 99.1 Sarepta Therapeutics Announces Preliminary Financial Results for the Third Quarter Ended September 30, 2021 CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) ? Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced preliminary financial results for its third quarter ended September 30, 2021. ? Sarepta expects its net produc |
|
| October 15, 2021 |
Exhibit 1.1 Execution Version 6,172,840 Shares Sarepta Therapeutics, Inc. Common Stock ($0.0001 par value) UNDERWRITING AGREEMENT October 13, 2021 Goldman Sachs & Co. LLC J.P. Morgan Securities LLC Morgan Stanley & Co. LLC Credit Suisse Securities (USA) LLC As Representatives of the several Underwriters c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 c/o J.P. Morgan Securities |
|
| October 15, 2021 |
Sarepta Therapeutics Announces Pricing of $500 Million Public Offering of Common Stock Exhibit 99.3 Sarepta Therapeutics Announces Pricing of $500 Million Public Offering of Common Stock CAMBRIDGE, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) ? Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has priced an underwritten public offering of 6,172,840 shares of its common stock at a price to the public of $81.00 per s |
|
| October 15, 2021 |
424B5 1 d239735d424b5.htm 424B5 Table of Contents CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered(1) Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, $0.0001 par value per share $575,000,046.00 $53,302.51 (1) The securities registered herein are offered pursuant to an automatic shelf registration statement. (2) Calculated purs |
|
| October 12, 2021 |
Subject to completion, dated October 12, 2021 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-229934 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has become effective under the Securities Act of 1933, as amended. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these secu |
|
| September 27, 2021 |
Sarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 Exhibit 99.1 Sarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA ? Company Anticipates Part B of MOMENTUM to Serve as Pivotal Study for SRP-5051 and to Seek Accelerated Approval if Successful ? Ambulatory and Non-Ambulatory Patients Between the Ages of 7 to 21 Will B |
|
| September 27, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2021 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Comm |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Sarepta Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 803607100 (CUSIP Number) July 30, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Risks UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREP |
|
| August 4, 2021 |
Exhibit 10.3 THIRD Amendment to License, Collaboration, and Option Agreement This THIRD AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT (this ?Third Amendment?) is made and entered into as of February 4, 2021 (the ?Third Amendment Effective Date?) between Sarepta Therapeutics Three LLC, a limited liability company organized and existing under the laws of the State of Delaware, United Sta |
|
| August 4, 2021 |
EX-10.4 5 srpt-ex104218.htm EX-10.4 Exhibit 10.4 FOURTH Amendment to License, Collaboration, and Option Agreement This FOURTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT (this “Fourth Amendment”) is made and entered into as of June 23, 2021 (the “Fourth Amendment Effective Date”) between Sarepta Therapeutics Three LLC, a limited liability company organized and existing under the laws |
|
| August 4, 2021 |
Exhibit 10.2 SECOND Amendment to License, Collaboration, and Option Agreement This SECOND AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT (this ?Second Amendment?) is made and entered into as of October 28, 2020 (the ?Second Amendment Effective Date?) between Sarepta Therapeutics Three LLC, a limited liability company organized and existing under the laws of the State of Delaware, United |
|
| August 4, 2021 |
Exhibit 10.1 FIRST Amendment to License, Collaboration, and Option Agreement This FIRST AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT (this ?First Amendment?) is made and entered into as of October 23, 2020 (the ?First Amendment Effective Date?) between Sarepta Therapeutics Three LLC, a limited liability company organized and existing under the laws of the State of Delaware, United Sta |
|
| June 3, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2021 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 18, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2021 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 18, 2021 |
EXHIBIT 99.1 Sarepta Therapeutics? Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy, SRP-9001, Demonstrates Robust Expression and Consistent Safety Profile Using Sarepta?s Commercial Process Material ? Results from the first 11 participants enrolled in Study 9001-103 ENDEAVOR showed robust transduction, delivering mean vector genome copies of 3.87 per nucleus ? Treated |
|
| May 18, 2021 |
Doug Ingram President and CEO May 18, 2021 8:30 a.m. ET Louise Rodino-Klapac, Ph.D. Executive Vice President and Chief Scientific Officer Clinical Update: Micro-dystrophin Gene Therapy Study SRP-9001-103: 12-Week Expression and Safety Data Using Commercially Representative Material EXHIBIT 99.2 EXHIBIT 99.2 Clinical Update: Micro-dystrophin Gene Therapy Study SRP-9001-103: 12-Week Expression and S |
|
| May 5, 2021 |
Quarterly Report - SRPT Q1 2021 10-Q Risks UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SARE |
|
| May 3, 2021 |
Doug Ingram President and CEO May 3, 2021 8:30 a.m. ET Clinical Update: Results from 30 mg/kg Cohort of MOMENTUM Study of SRP-5051 for Duchenne Muscular Dystrophy Gilmore o?neill, mb, mmsc Executive Vice President, R&D and Chief Medical Officer EXHIBIT 99.2 Sarepta therapeutics inc 2021 all rights reserved 1 logo Welcome and Introduction Doug Ingram President and CEO Sarepta therapeutics inc 2021 |
|
| May 3, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2021 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 3, 2021 |
EXHIBIT 99.1 Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51 ? Results suggest a highly potent next-generation treatment that could offer greater efficacy with less frequent dosing ? SRP-5051 dosed monthly at 30 mg/kg delivered mean exon skipping of 10.79% and mean dystrophin ex |
|
| April 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 1, 2021 |
EXHIBIT 10.58 SEPARATION AND CONSULTING AGREEMENT AND GENERAL RELEASE This Separation and Consulting Agreement and General Release (the ?Agreement?) by and between David Tyronne Howton, Jr. (?Employee?) and Sarepta Therapeutics, Inc. (the ?Company?), is made effective as of the date following Employee?s signature and the expiration of the seven (7) day revocation period without revocation (the ?Ef |
|
| March 1, 2021 |
EXHIBIT 10.61 December 14, 2020 Ian Estepan Dear Ian, On behalf of Sarepta?s entire management team, I would like to congratulate you on your promotion to EVP, Chief Financial Officer. Your new 2020 annual base salary will be $525,000, subject to applicable taxes and withholdings. Your new salary will be effective on December 14, 2020 and will be paid on a pro rata basis for 2020. It will be paid |
|
| March 1, 2021 |
Offer Letter dated by December 18, 2014 and between Sarepta Therapeutics, Inc. and Ian M. Estepan EXHIBIT 10.62 December 18, 2014 Ian Estepan [XXX] [XXX] Dear Ian: On behalf of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company"), it is a great pleasure to extend you this offer of employment as Senior Director, Corporate Affairs in Cambridge, MA effective on a January 1, 2015 ( "Hire Date"), reporting to Chris Garabedian, CEO. Base Salary. In this position, you will earn an annual base sala |
|
| March 1, 2021 |
Subsidiaries of the Registrant. EXHIBIT 21.1 Sarepta Therapeutics, Inc. Subsidiaries of the Registrant Name Jurisdiction of Incorporation Sarepta Securities Corp. Massachusetts, USA ST International Holdings Two, Inc. Delaware, USA Sarepta Therapeutics Three, LLC Delaware, USA |
|
| March 1, 2021 |
Annual Report - SRPT 12/31/2020 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number : 001-14895 Sarepta Thera |
|
| March 1, 2021 |
Offer Letter dated April 19, 2018 by and between Sarepta Therapeutics, Inc. and Louise Rodino-Klapac EXHIBIT 10.60 April 19, 2018 Louise Rodino-Klapac [XXXX] [XXXX] Dear Louise, On behalf of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company"), It is a great pleasure to extend you this offer of employment as Vice President, Gene Therapy on a date agreed upon following your acceptance of this offer ("Hire Date"), reporting to Doug Ingram, President & Chief Executive Officer. Base Salary. In thi |
|
| March 1, 2021 |
EXHIBIT 10.59 December 14, 2020 Louise Rodino-Klapac, Ph.D. Dear Louise, On behalf of Sarepta?s entire management team, I would like to congratulate you on your promotion to EVP, Chief Scientific Officer. Your new 2020 annual base salary will be $550,000, subject to applicable taxes and withholdings. Your new salary will be effective on December 14, 2020 and will be paid on a pro rata basis for 20 |
|
| March 1, 2021 |
Offer Letter dated March 17, 2017 by and between Sarepta Therapeutics, Inc. and Joseph Bratica EXHIBIT 10.63 Friday, March 17th Joseph Bratica [XXX] [XXX] Dear Joe: On behalf of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company"), it is a great pleasure to extend you this offer of employment as Controller in Cambridge , MA effective on a date agreed upon following your acceptance of this offer ("Hire Date"), reporting to Sandy Mahatme, Executive Vice President, Chief Financial Officer & |
|
| February 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Sarepta Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 803607100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| February 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Sarepta Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 803607100 (CUSIP Number) January 29, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Sarepta Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 803607100 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| January 11, 2021 |
Our mission continues. DOUGLAS INGRAM President and Chief Executive Officer JP Morgan 39th Annual Healthcare Conference 2021 January 11, 2021 Armed with the most advanced science in genetic medicine, we are in a daily race to rescue lives otherwise stolen by rare disease. At Sarepta, every day is another twenty-four hours to stand up for patients, advance technology, challenge convention, and drag |
|
| January 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 7, 2021 |
Micro-dystrophin SRP-9001-102 Top-line Clinical Data (Part One) Doug Ingram President and Chief Executive Officer Louise Rodino-Klapac, Ph. |
|
| January 7, 2021 |
EX-99.1 2 srpt-ex99134.htm EX-99.1 Exhibit 99.1 Sarepta Therapeutics Announces Top-line Results for Part 1 of Study 102 Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy - Study met the primary biological endpoint of micro-dystrophin protein expression at 12 weeks post-treatment, as measured by western blot, in SRP-9001-treated participants vers |
|
| January 7, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2021 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| December 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2020 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 5, 2020 |
Quarterly Report - Q3 2020 10-Q Risks UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 |
|
| November 5, 2020 |
EXHIBIT 10.1 FIRST AMENDMENT TO LOAN AGREEMENT This First Amendment to the Loan Agreement (defined below) (this “Amendment”), dated as of September 24, 2020 (the “Effective Date”), is entered into by and among SAREPTA THERAPEUTICS, INC., a Delaware corporation (as “Borrower”), on its own behalf and on behalf of each other Credit Party (if any), BIOPHARMA CREDIT PLC, a public limited company incorp |
|
| September 25, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2020 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Comm |
|
| September 9, 2020 |
EX-99.1 2 srpt-ex99141.htm EX-99.1 EXHIBIT 99.1 Sarepta Therapeutics Provides Program Update for SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy CAMBRIDGE, Mass., Sept. 9, 2020 – Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has completed a Type C ‘written response only’ meet |
|
| September 9, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2020 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 5, 2020 |
S-8 1 srpt-s8.htm S-8 As filed with the Securities and Exchange Commission on August 5, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Sarepta Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 93-0797222 (State or other jurisdiction of incorporation |
|
| August 5, 2020 |
Separation Agreement and General Release between Sandesh Mahatme and Sarepta Therapeutics, Inc. EXHIBIT 10.2 SEPARATION AGREEMENT AND GENERAL RELEASE This Separation Agreement and General Release (the “Agreement”) by and between Sandesh Mahatme (“Employee”) and Sarepta Therapeutics, Inc. (the “Company” or “Sarepta”), is made effective as of the date following Employee’s signature and the expiration of the seven (7) day revocation period without revocation (the “Effective Date”) with referenc |
|
| August 5, 2020 |
Quarterly Report - Q2 2020 10-Q Risks UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREP |
|
| August 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2020 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| June 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2020 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 8, 2020 |
Amendment No. 1 to the Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan EX-10.1 3 srpt-ex10125.htm EX-10.1 Exhibit 10.1 AMENDMENT NO. 1 TO THE SAREPTA THERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN WHEREAS, Sarepta Therapeutics, Inc. (the “Company”) previously adopted and approved the 2018 Equity Incentive Plan (the “Plan”); WHEREAS, pursuant to Section 20 of the Plan, the “Administrator” (defined under the Plan as the Board of Directors of the Company (the “Board”) or |
|
| June 8, 2020 |
Exhibit 99.1 Sarepta Therapeutics Announces Positive Expression and Functional Data From the SRP-9003 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E - In post-treatment muscle biopsies, clinical trial participants in the high-dose cohort showed a dose-dependent increase in transduction and expression when compared with the low-dose cohort, with a mean of 72% beta-sarcoglycan (b |
|
| June 8, 2020 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SAREPTA THERAPEUTICS, INC. Sarepta Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “DGCL”), DOES HEREBY CERTIFY: FIRST: The name of the Corporation is Sarepta Therapeutics, In |
|
| June 8, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2020 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 8, 2020 |
Welcome and Introduction Doug Ingram President and CEO Sarepta Therapeutics, Inc. EX-99.2 3 srpt-ex99218.htm EX-99.2 Clinical Update: SRP-9003 Beta-Sarcoglycanopathy Gene Therapy Program Limb-Girdle Muscular Dystrophy Type 2E Cambridge, MA June 8, 2020 Exhibit 99.2 SAREPTA THERAPEUTICS, INC. 2020. ALL RIGHTS RESERVED. 1 Forward-Looking Statements This presentation contains "forward-looking statements." Any statements contained in this presentation that are not statements of his |
|
| June 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2020 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 6, 2020 |
Quarterly Report - Q1 2020 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREPTA TH |
|
| April 21, 2020 |
SRPT / Sarepta Therapeutics, Inc. DEF 14A - - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 21, 2020 |
SRPT / Sarepta Therapeutics, Inc. DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 15, 2020 |
ROPES & GRAY LLP PRUDENTIAL TOWER 800 BOYLSTON STREET BOSTON, MA 02199-3600 WWW.ROPESGRAY.COM April 15, 2020 BY EDGAR TRANSMISSION Re: Sarepta Therapeutics, Inc. Preliminary Proxy Statement on Schedule 14A Filed on April 8, 2020 by Sarepta Therapeutics, Inc. SEC Comment Letter dated April 13, 2020 File No. 001-14895 Ladies and Gentlemen: On behalf of Sarepta Therapeutics, Inc. (the “Company”), we |
|
| April 8, 2020 |
SRPT / Sarepta Therapeutics, Inc. PRE 14A - - PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 19, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2020 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 26, 2020 |
EXHIBIT 10.54 GUARANTY AND SECURITY AGREEMENT Dated as of December 20, 2019 by SAREPTA THERAPEUTICS, INC. (as Borrower), THE GUARANTORS PARTY HERETO, and Each OTHER Grantor From Time to Time Party Hereto in favor of BIOPHARMA CREDIT PLC (as Collateral Agent on behalf of Lenders and the other Secured Parties) GUARANTY AND SECURITY AGREEMENT, dated as of December 20, 2019 by SAREPTA THERAPEUTICS, IN |
|
| February 26, 2020 |
EXHIBIT 10.56 November 11, 2019 William Ciambrone [**] Dear Bill, On behalf of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”), it is a great pleasure to extend you this offer of employment as Executive Vice President, Technical Operations in the Andover, Massachusetts, office effective on a date agreed upon following your acceptance of this offer (“Hire Date”), reporting to Douglas Ingram |
|
| February 26, 2020 |
EXECUTION VERSION EXHIBIT 10.52 STOCK PURCHASE AGREEMENT By and Between Sarepta Therapeutics, Inc. and Roche Finance Ltd Dated December 21, 2019 Table of Contents Page Section 1. Purchase and Sale of Common Stock 1 1.1. Sale and Issuance of Common Stock 1 1.2. Payment 1 1.3. Closing; Delivery 1 1.4. No Registration. 1 1.5. Defined Terms Used in this Agreement 2 1.6. No Strict Construction; Interpr |
|
| February 26, 2020 |
EXHIBIT 10.53 EXECUTION VERSION LOAN AGREEMENT Dated as of December 13, 2019 among SAREPTA THERAPEUTICS, INC. (as Borrower), THE GUARANTORS PARTY HERETO, BIOPHARMA CREDIT PLC (as Collateral Agent and a Lender), and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP (as a Lender) LOAN AGREEMENT THIS LOAN AGREEMENT (this “Agreement”), dated as of December 13, 2019 (the “Effective Date”) by and among SAREPTA |
|
| February 26, 2020 |
Annual Report - 2019 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number : 001-14895 Sarepta Thera |
|
| February 26, 2020 |
Subsidiaries of the Registrant. EXHIBIT 21.1 Sarepta Therapeutics, Inc. Subsidiaries of the Registrant Name Jurisdiction of Incorporation Sarepta Securities Corp. Massachusetts, USA Myonexus Therapeutics, Inc. Delaware, USA ST International Holdings Two, Inc. Delaware, USA Sarepta Therapeutics Three, LLC Delaware, USA |
|
| February 26, 2020 |
Description of Registered Securities Exhibit 4.4 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of the common stock, par value $0.0001 per share, of Sarepta Therapeutics, Inc. (the “Company”, “us”, “we”, or “our”). For the complete terms of our common stock, please refer to our articles of in |
|
| February 26, 2020 |
EXHIBIT 10.51 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO SAREPTA THERAPEUTICS, INC. IF PUBLICLY DISCLOSED. License, Collaboration, and Option Agreement By and Between Sarepta Therapeutics Three, LLC and F. Hoffmann-La Roche Ltd Dated December 21, 2019 7944584310 TABLE OF CONTENT |
|
| February 26, 2020 |
Amendment to Offer Letter by and between Sarepta Therapeutics, Inc. and William F. Ciambrone EXHIBIT 10.57 November 15, 2019 William Ciambrone [**] Re: Amendment to Offer Letter of November 11, 2019 Dear Bill, This letter amends the offer letter previously signed by you dated November 11, 2019 (the “Offer Letter”) to correct the reference to the Company equity plan under which your option award will be granted. Except as specifically set forth below, all provisions of the Offer Letter wil |
|
| February 26, 2020 |
EXHIBIT 10.55 SAREPTA THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (As adopted December 10, 2019) Sarepta Therapeutics, Inc. (the “Company”) believes that the granting of equity and cash compensation to its directors represents a powerful tool to attract, retain and reward directors who are not employees of the Company (“Outside Directors”) and to align the interests of our Outside |
|
| February 21, 2020 |
Amendment No. 2 to the Sarepta Therapeutics, Inc. 2014 Employment Commencement Incentive Plan Exhibit 10.1 AMENDMENT NO. 2 TO THE SAREPTA THERAPEUTICS, INC. 2014 EMPLOYMENT COMMENCEMENT INCENTIVE PLAN WHEREAS, Sarepta Therapeutics, Inc. (the “Company”) previously adopted and approved the 2014 Employment Commencement Incentive Plan (the “Plan”) as an inducement stock plan under Nasdaq Stock Market Rule 5635(c)(4) to, among other things, attract and retain the best candidates for positions o |
|
| February 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2020 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 18, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2020 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 12, 2020 |
SRPT / Sarepta Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Sarepta Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 803607100 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is fil |
|
| January 13, 2020 |
Amendment No. 1 to the Amended and Restated Bylaws. Exhibit 3.1 AMENDMENT NO. 1 TO AMENDED AND RESTATED BYLAWS OF SAREPTA THERAPEUTICS, INC. (a Delaware corporation) The Bylaws of Sarepta Therapeutics, Inc., a Delaware corporation, are hereby amended by replacing the text of Article III, Section 3.02 with the following: “The authorized number of directors shall be determined from time to time by resolution of the Board, provided the Board shall con |
|
| January 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2020 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 13, 2020 |
EX-99.1 2 srpt-ex9916.htm EX-99.1 Forward-looking statements This presentation contains "forward-looking statements." Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believe,” “anticipate,” “plan,” “expect,” “will,” “may,” “intend,” “prepare,” “look,” “potential,” “possible” and similar expressions are intended to identify fo |
|
| January 13, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2020 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 23, 2019 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2019 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 13, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2019 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 14, 2019 |
EX-4.5 2 d829912dex45.htm EX-4.5 Exhibit 4.5 REGISTRATION RIGHTS AGREEMENT By and Between STRIDEBIO, INC. AND SAREPTA THERAPEUTICS, INC. Dated as of November 13, 2019 TABLE OF CONTENTS 1. Definitions 1 2. Registration Rights 4 2.1 Registration Statement 4 2.2 Obligations of the Company 4 2.3 Stand-down Period 6 2.4 Furnish Information 6 2.5 Expenses 6 2.6 Indemnification 6 2.7 SEC Reports 8 2.8 As |
|
| November 14, 2019 |
SRPT / Sarepta Therapeutics, Inc. S-3ASR - - S-3ASR S-3ASR 1 d829912ds3asr.htm S-3ASR Table of Contents As filed with the Securities and Exchange Commission on November 14, 2019 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SAREPTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 93-0797222 (State or oth |
|
| November 7, 2019 |
Quarterly Report - Q3 2019 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREPT |
|
| October 4, 2019 |
EX-99.2 3 srpt-ex99244.htm EX-99.2 Louise Rodino-Klapac Senior Vice President, Gene Therapy Sarepta Therapeutics, Inc. October 4, 2019 Clinical Update: srp-9003 Beta-Sarcoglycanopathy Gene Therapy program Limb-Girdle Muscular Dystrophy Type 2E FUNCTIONAL DATA Exhibit 99.2 Forward-Looking Statements This presentation contains "forward-looking statements." Any statements that are not statements of h |
|
| October 4, 2019 |
EX-99.1 2 srpt-ex9916.htm EX-99.1 Exhibit 99.1 Sarepta Therapeutics Announces Positive Functional Results from the SRP-9003 (MYO-101) Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy - Improvements on functional measures seen in all three participants - - Significant reduction in creatine kinase maintained over nine months - - Results follow positive an |
|
| October 4, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2019 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| September 11, 2019 |
SRPT / Sarepta Therapeutics, Inc. S-8 - - S-8 S-8 1 d801842ds8.htm S-8 As filed with the Securities and Exchange Commission on September 11, 2019 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Sarepta Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 93-0797222 (State or other jurisdiction of incorpo |
|
| August 19, 2019 |
Exhibit 99.1 Sarepta Therapeutics Receives Complete Response Letter from the US Food and Drug Administration for Golodirsen New Drug Application CAMBRIDGE, Mass., August 19, 2019 (GLOBE NEWSWIRE) – Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced it had received a Complete Response Letter (CRL) from the U.S. Food and Drug Adminis |
|
| August 19, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2019 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 8, 2019 |
EX-99.1 2 srpt-ex99115.htm EX-99.1 Exhibit 99.1 Sarepta Therapeutics Comments on Erroneous Submission to US FDA Adverse Event Reporting System (FAERS) CAMBRIDGE, Mass., August 8, 2019 (GLOBE NEWSWIRE) - Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, was informed earlier today that an adverse event report was erroneously submitted to the FDA’s |
|
| August 8, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2019 Sarepta Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-14895 93-0797222 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 7, 2019 |
Quarterly Report - Q2 2019 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREPTA THE |
|
| August 7, 2019 |
Sub-Plan for Japan under the Sarepta Therapeutics, Inc. 2014 Employment Commencement Incentive Plan EX-10.3 4 srpt-ex103241.htm EX-10.3 EXHIBIT 10.3 Sarepta Therapeutics, Inc. 2014 Employment Commencement Incentive Plan Schedule – Japan Sub-Plan This Schedule applies to any Award that is made to an employee of Sarepta Therapeutics K.K. who has not previously been an Employee or Director of Sarepta Therapeutics K.K., the Company or a Subsidiary, or who is commencing employment with Sarepta Therap |
|
| August 7, 2019 |
EXHIBIT 10.4 AMENDMENT NO. 1 TO THE SAREPTA THERAPEUTICS, INC. AMENDED AND RESTATED 2013 Employee Stock Purchase Plan (AS AMENDED AND RESTATED On JUNE 27, 2016) WHEREAS, Sarepta Therapeutics, Inc. (the “Company”) previously adopted and approved the Amended and Restated 2013 Employee Stock Purchase Plan (as Amended and Restated as of June 27, 2016) (the “Plan”); WHEREAS, pursuant to Section 18(a) o |
|
| August 7, 2019 |
Sub-Plan for Japan under the Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan EXHIBIT 10.2 Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan Schedule – Japan Sub-Plan This Schedule applies to any Awards that are made to directors, employees or other service providers, including but not limited to consultants, of Sarepta Therapeutics K.K. (“Japan Participants”) under the Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan (the “2018 Plan”). The 2018 Plan, as amended by |
|
| August 7, 2019 |
[**] = Identified information has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. |
|
| June 7, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2019 Sarepta Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-14895 93-0797222 (State or other Jurisdiction of Incorporation) (Commission |
